As the drug development pipeline shifts toward complex biologics, traditional oral or frequent dosing regimens are being replaced by long-acting formulations, reveals David Westberg from Nanexa.

According to Sven Lee from Bionova, the era of predictable, plug-and-play bioprocessing platforms is coming to an end as novel advanced pipelines now require bespoke, early-stage intervention to ensure molecular quality.

The deal centers on two FDA-reviewed NSCLC therapies with potential best-in-class profiles that will accelerate GSK’s expansion into lung cancer and support near-term growth alongside the company’s broader oncology strategy.

A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily treatments with no new safety concerns identified in treatment-experienced patient population.

Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

Backed by USD 101 million in cumulative financing, Ethyreal Bio is targeting the shared pathogenic driver of Graves' disease and thyroid eye disease with a differentiated, long-acting subcutaneous antibody.

A novel pan-sarbecovirus vaccine candidate developed by the University of Cambridge and DIOSynVax has demonstrated safety in a Phase I, needle-free clinical trial.

SPONSORED CONTENT: Pedro Fernandes Botas and Mark Macdonald from Codis break down how advanced spray drying capabilities, mathematical modeling, and commercial operations experience are helping sponsors navigate the modern formulation landscape.

The objective of the joint research collaboration between Circio and GenAssist is to evaluate potential synergy between the companies’ complementary technologies for the development of next-gen AAVs.

As specialized modalities push classical manufacturing models to their limits, organizations must treat internal talent development with the same level of process excellence they apply to biological pipelines.

A newly signed USD 1.9 billion global research collaboration and licensing agreement is set to combine Ascidian Therapeutics’ exon editing platform with Eli Lilly’s expertise in genetic medicines.

AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer evidence that early intervention improves long-term outcomes for patients with advanced breast cancer.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company will enable the pharma giant to build a pipeline targeting viral and bacterial pathogens linked to long-term neurological and oncological risks.

As the pharmaceutical supply chain digitizes, the unique human element of face-to-face networking remains fundamental, according to Sherma Ellis-Daal, Brand Director for CPHI Americas.

Ahead of CPHI Americas, Kent Payne from Wilmington PharmaTech reveals how shifting geopolitical regulations, private equity capital, and specialized technical expertise are driving domestic pharmaceutical manufacturing.

Ahead of its exhibition at CPHI Americas, Curia announced the completion of its Spanish aseptic upgrades alongside concurrent sterile vial filling and lyophilization expansions underway in Glasgow.

Industry leaders are set to gather in Philadelphia to address fluctuating policy shifts, supply chain risks, and accelerating biologics investment across the global industry.

As bio/pharmaceutical drug development progresses and more complex molecules enter the pipeline, increased innovation and a rethink of excipient portfolios is necessary.

Marking Clinical Trial Awareness Day, Treehill Partners’ CEO Ali Pashazadeh details the flaws in clinical study designs and explains how high-velocity competition from Eastern markets is forcing a long-overdue industry redesign.

The company’s expanded stability storage hub now delivers a wide spectrum of ICH-compliant and ultra-low-temperature solutions, addressing growing needs for stability data and GMP analytical support across complex drug programs.